<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00892957</url>
  </required_header>
  <id_info>
    <org_study_id>550801</org_study_id>
    <nct_id>NCT00892957</nct_id>
  </id_info>
  <brief_title>FS VH S/D 500 S-apr in Vascular Surgery</brief_title>
  <official_title>Clinical Evaluation of Efficacy and Safety of FS VH S/D 500 S-apr for Hemostasis in Subjects Undergoing Vascular Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baxter Healthcare Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to compare safety and efficacy of FS VH S/D 500 s-apr (FS)
      versus manual compression in prosthetic expanded polytetrafluoroethylene (ePTFE) graft
      placement.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Achieved Hemostasis at 4 Minutes Post Treatment Application.</measure>
    <time_frame>4 minutes post start of treatment application</time_frame>
    <description>Hemostasis at the study suture line must be maintained until closure of the surgical wound.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemostasis at 4 Minutes After Treatment Application at the Suture Line by Bleeding Severity - Moderate Bleeding</measure>
    <time_frame>4 minutes post start of treatment application</time_frame>
    <description>Investigators were shown videos of bleeding severities to standardize assessments.
Moderate bleeding defined as:
Either &gt;25% of the suture line bleeds, or
≥5 suture line bleedings were present, if counting of suture line bleedings was possible, or
1 pulsatile suture line bleeding was present.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemostasis at 4 Minutes After Treatment Application at the Suture Line by Bleeding Severity - Severe Bleeding</measure>
    <time_frame>4 minutes post start of treatment application</time_frame>
    <description>Investigators were shown videos of bleeding severities to standardize assessments.
Severe bleeding defined as:
Either &gt;50% of the suture line bleeds, or
≥10 suture line bleedings were present, if counting of suture line bleedings was possible, or
&gt;1 pulsatile suture line bleeding was present, or
≥1 spurting suture line bleeding was present.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved Hemostasis at 6 Minutes Post Treatment Application</measure>
    <time_frame>6 minutes post start of treatment application</time_frame>
    <description>Hemostasis at the study suture line must be maintained until closure of the surgical wound.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved Hemostasis at 10 Minutes Post Treatment Application</measure>
    <time_frame>10 minutes post start of treatment application</time_frame>
    <description>Hemostasis at the study suture line must be maintained until closure of the surgical wound.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Intraoperative Rebleeding After Hemostasis at Study Suture Line</measure>
    <time_frame>Intraoperative day 0</time_frame>
    <description>Intraoperative rebleeding at the study suture line after occurrence of hemostasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Postoperative Rebleeding</measure>
    <time_frame>Postoperative through day 30 ± 5</time_frame>
    <description>Any rebleeding requiring surgical re-exploration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Graft Occlusion</measure>
    <time_frame>post-op discharge/day 1, post-op day 14 and day 30</time_frame>
    <description>Determined clinically and defined as absence of blood flow through the graft.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Infection at the Surgical Site</measure>
    <time_frame>post-op discharge/day 1, post-op day 14 and day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Infections by Grade</measure>
    <time_frame>post-op discharge/day 1, post-op day 14 and day 30</time_frame>
    <description>Infections were recorded according to:
Grade I: only dermis affected
Grade II: infection invades subcutaneous region but not the arterial implant
Grade III: the arterial implant is infected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs: Systolic and Diastolic Blood Pressure (BP)- Preoperative Baseline</measure>
    <time_frame>Within 14 days prior to date of surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Vital Signs: Systolic and Diastolic Blood Pressure</measure>
    <time_frame>Within 14 days prior to surgery through postoperative day 14</time_frame>
    <description>Percent Change in Systolic and Diastolic Blood Pressure (BP) Measured as: Preoperative Baseline - Intraoperative Day 0; Preoperative Baseline - Postoperative Day 1; and Preoperative Baseline - Postoperative Day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs: Heart Rate - Preoperative Baseline</measure>
    <time_frame>Within 14 days prior to date of surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Vital Signs: Heart Rate</measure>
    <time_frame>Within 14 days prior to surgery through postoperative day 14</time_frame>
    <description>Percent Change in Heart Rate Measured as: Preoperative Baseline - Intraoperative Day 0; Preoperative Baseline - Postoperative Day 1; and Preoperative Baseline - Postoperative Day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs: Respiratory Rate - Preoperative Baseline</measure>
    <time_frame>Within 14 days prior to date of surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Vital Signs: Respiratory Rate</measure>
    <time_frame>Within 14 days prior to surgery through postoperative day 14</time_frame>
    <description>Percent Change in Heart Rate Measured as: Preoperative Baseline - Postoperative Day 1; and Preoperative Baseline - Postoperative Day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Values Over Time: Hemoglobin</measure>
    <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Values Over Time: Hematocrit</measure>
    <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Values Over Time: Erythrocytes</measure>
    <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Values Over Time: Leukocytes, Basophils, Eosinophils, Lymphocytes, Neutrophils, and Monocytes</measure>
    <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Values Over Time: Platelets</measure>
    <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Values Over Time: Creatinine, Bilirubin, and Blood Urea Nitrogen (BUN)</measure>
    <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Values Over Time: Alanine Aminotransferase (ALT)</measure>
    <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Values Over Time: Aspartate Aminotransferase (AST)</measure>
    <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Values Over Time: Activated Partial Thromboplastin Time (aPTT)</measure>
    <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Values Over Time: International Normalized Ratio(INR)</measure>
    <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">176</enrollment>
  <condition>Hemostasis in Participants Receiving Peripheral Vascular Expanded Polytetrafluoroethylene (ePTFE) Graft Prostheses</condition>
  <arm_group>
    <arm_group_label>FS VH S/D 500 s-apr</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FS VH S/D 500 s-apr will be applied to the study suture line.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Manual compression with surgical gauze pads</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dry gauze pads will be positioned to cover the complete study suture line.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr)</intervention_name>
    <description>The actual dose of FS VH S/D 500 s-apr will depend on the length of the suture line and the intensity of bleeding (but shall not exceed 4 mL FS VH S/D 500 s-apr).</description>
    <arm_group_label>FS VH S/D 500 s-apr</arm_group_label>
    <other_name>Biological two-component fibrin sealant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Surgical gauze pads</intervention_name>
    <description>Manual compression with surgical gauze pads</description>
    <arm_group_label>Manual compression with surgical gauze pads</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Preoperative inclusion criteria:

          -  Subjects undergoing vascular surgery (ie, conduit placement with an ePTFE graft),
             including arterio-arterial bypasses, including:

               -  axillo-femoral

               -  axillo-bifemoral

               -  aorto-bifemoral

               -  ilio-femoral

               -  femoro-femoral

               -  ilio-popliteal

               -  femoro-popliteal (including below knee)

               -  femoro-tibial vessel bypass

               -  arterio-venous shunting for dialysis access in the upper or lower extremity

          -  Signed informed consent

          -  Subject is of childbearing potential, presents with a negative serum or urine
             pregnancy test, and agrees to employ adequate birth control measures for the duration
             of the study.

          -  Subject is willing and able to comply with the requirements of the protocol.

        Intraoperative inclusion criterion:

          -  Suture line bleeding eligible for study treatment is present after surgical hemostasis
             (ie, suturing). (A definition of eligible suture line bleeding is provided in the
             study protocol.)

        Exclusion Criteria:

        Preoperative exclusion criteria:

          -  Other vascular procedures during the same surgical session (stenting and/or
             endarterectomy of the same artery are allowed)

          -  Congenital coagulation disorders

          -  Prior kidney transplantation

          -  Heparin-induced thrombocytopenia

          -  Known hypersensitivity to heparin

          -  Known hypersensitivity to aprotinin or other components of the product

          -  Known severe congenital or acquired immunodeficiency (eg, HIV infection or long-term
             treatment with immunosuppressive drugs (eg, organ transplantation patients)

          -  Prior radiation therapy to the operating field

          -  Severe local inflammation at the operating field

          -  Subject is pregnant or lactating at the time of enrollment

          -  Subject has participated in another clinical study involving an investigational
             product (IP) or investigational device within 30 days prior to enrollment or is
             scheduled to participate in another clinical study involving an IP or investigational
             device during the course of this study

          -  Subject has previously participated in this study (Protocol No.: 550801), ie, each
             subject can only be enrolled once.

        Intraoperative Exclusion Criteria:

          -  Major intraoperative complications that require resuscitation or deviation from the
             planned surgical procedure

          -  Intraoperative change in planned surgical procedure, which results in subject no
             longer meeting preoperative inclusion and/or exclusion criteria, (eg, abandonment of
             ePTFE graft placement)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabella Presch, MD, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Baxter Innovations GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orange</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Saha SP, Muluk S, Schenk W 3rd, Dennis JW, Ploder B, Grigorian A, Presch I, Goppelt A. A prospective randomized study comparing fibrin sealant to manual compression for the treatment of anastomotic suture-hole bleeding in expanded polytetrafluoroethylene grafts. J Vasc Surg. 2012 Jul;56(1):134-41. doi: 10.1016/j.jvs.2012.01.009. Epub 2012 May 25.</citation>
    <PMID>22633423</PMID>
  </reference>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2009</study_first_submitted>
  <study_first_submitted_qc>May 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2009</study_first_posted>
  <results_first_submitted>September 13, 2012</results_first_submitted>
  <results_first_submitted_qc>October 26, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 27, 2012</results_first_posted>
  <disposition_first_submitted>December 2, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>December 2, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 8, 2011</disposition_first_posted>
  <last_update_submitted>October 26, 2012</last_update_submitted>
  <last_update_submitted_qc>October 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vascular Surgery</keyword>
  <keyword>Arterio-arterial bypasses</keyword>
  <keyword>Arterio-venous (AV) shunts</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombin</mesh_term>
    <mesh_term>Fibrin Tissue Adhesive</mesh_term>
    <mesh_term>Aprotinin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were enrolled at 24 clinical sites in the United States, beginning July 2009 and completing in October 2010</recruitment_details>
      <pre_assignment_details>176 participants were enrolled. 32 were screen failures. 1 was withdrawn by investigator (study coordinator not available to collect data), 2 participants requested withdrawal, 1 participant died prior to screening and prior to receiving study treatment. Therefore, 140 of the 176 enrolled were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>FS VH S/D 500 S-apr</title>
          <description>FS VH S/D 500 s-apr will be applied to the study suture line.</description>
        </group>
        <group group_id="P2">
          <title>Control - Manual Compression With Surgical Gauze Pads</title>
          <description>Dry gauze pads will be positioned to cover the complete study suture line.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Intraoperative Day 0</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Postoperative Day 1 Assessment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Between Postoperative Day 1 and Day 14</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Postoperative Day 14 Assessment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="68">Two participants missed postoperative Day 14 assessment, both returned for Day 30 postop assessment</participants>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Postoperative Day 30 Assessment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="70">Two participants missed postoperative Day 14 assessment, both returned for Day 30 postop assessment</participants>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>FS VH S/D 500 S-apr</title>
          <description>FS VH S/D 500 s-apr will be applied to the study suture line.</description>
        </group>
        <group group_id="B2">
          <title>Control - Manual Compression With Surgical Gauze Pads</title>
          <description>Dry gauze pads will be positioned to cover the complete study suture line.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="70"/>
            <count group_id="B2" value="70"/>
            <count group_id="B3" value="140"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.5" spread="12.6"/>
                    <measurement group_id="B2" value="66.3" spread="11.5"/>
                    <measurement group_id="B3" value="64.4" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Achieved Hemostasis at 4 Minutes Post Treatment Application.</title>
        <description>Hemostasis at the study suture line must be maintained until closure of the surgical wound.</description>
        <time_frame>4 minutes post start of treatment application</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>FS VH S/D 500 S-apr</title>
            <description>FS VH S/D 500 s-apr was applied to the study suture line</description>
          </group>
          <group group_id="O2">
            <title>Control - Manual Compression With Surgical Gauze</title>
            <description>Dry gauze pads were positioned to cover the complete study suture line</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved Hemostasis at 4 Minutes Post Treatment Application.</title>
          <description>Hemostasis at the study suture line must be maintained until closure of the surgical wound.</description>
          <population>Intent to Treat</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.9" lower_limit="51.2" upper_limit="73.6"/>
                    <measurement group_id="O2" value="31.4" lower_limit="21.4" upper_limit="42.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Likelihood ratio chi-square test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved Hemostasis at 6 Minutes Post Treatment Application</title>
        <description>Hemostasis at the study suture line must be maintained until closure of the surgical wound.</description>
        <time_frame>6 minutes post start of treatment application</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>FS VH S/D 500 S-apr</title>
            <description>FS VH S/D 500 s-apr was applied to the study suture line</description>
          </group>
          <group group_id="O2">
            <title>Control - Manual Compression With Surgical Gauze</title>
            <description>Dry gauze pads were positioned to cover the complete study suture line</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved Hemostasis at 6 Minutes Post Treatment Application</title>
          <description>Hemostasis at the study suture line must be maintained until closure of the surgical wound.</description>
          <population>Intent to treat</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4" lower_limit="60.2" upper_limit="81.1"/>
                    <measurement group_id="O2" value="42.9" lower_limit="31.7" upper_limit="54.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Likelihood ratio chi-square test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved Hemostasis at 10 Minutes Post Treatment Application</title>
        <description>Hemostasis at the study suture line must be maintained until closure of the surgical wound.</description>
        <time_frame>10 minutes post start of treatment application</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>FS VH S/D 500 S-apr</title>
            <description>FS VH S/D 500 s-apr was applied to the study suture line</description>
          </group>
          <group group_id="O2">
            <title>Control - Manual Compression With Surgical Gauze</title>
            <description>Dry gauze pads were positioned to cover the complete study suture line</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved Hemostasis at 10 Minutes Post Treatment Application</title>
          <description>Hemostasis at the study suture line must be maintained until closure of the surgical wound.</description>
          <population>Intent to treat</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.7" lower_limit="64.9" upper_limit="84.7"/>
                    <measurement group_id="O2" value="55.7" lower_limit="44.0" upper_limit="67.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>Likelihood ratio chi-square test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Intraoperative Rebleeding After Hemostasis at Study Suture Line</title>
        <description>Intraoperative rebleeding at the study suture line after occurrence of hemostasis.</description>
        <time_frame>Intraoperative day 0</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>FS VH S/D 500 S-apr</title>
            <description>FS VH S/D 500 s-apr was applied to the study suture line</description>
          </group>
          <group group_id="O2">
            <title>Control - Manual Compression With Surgical Gauze</title>
            <description>Dry gauze pads were positioned to cover the complete study suture line</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Intraoperative Rebleeding After Hemostasis at Study Suture Line</title>
          <description>Intraoperative rebleeding at the study suture line after occurrence of hemostasis.</description>
          <population>Intent to treat</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" lower_limit="1.8" upper_limit="12.8"/>
                    <measurement group_id="O2" value="1.4" lower_limit="0.1" upper_limit="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.158</p_value>
            <method>Likelihood ratio chi-square test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Postoperative Rebleeding</title>
        <description>Any rebleeding requiring surgical re-exploration</description>
        <time_frame>Postoperative through day 30 ± 5</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>FS VH S/D 500 S-apr</title>
            <description>FS VH S/D 500 s-apr was applied to the study suture line</description>
          </group>
          <group group_id="O2">
            <title>Control - Manual Compression With Surgical Gauze</title>
            <description>Dry gauze pads were positioned to cover the complete study suture line</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Postoperative Rebleeding</title>
          <description>Any rebleeding requiring surgical re-exploration</description>
          <population>Intent to treat</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="5.1"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Graft Occlusion</title>
        <description>Determined clinically and defined as absence of blood flow through the graft.</description>
        <time_frame>post-op discharge/day 1, post-op day 14 and day 30</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>FS VH S/D 500 S-apr</title>
            <description>FS VH S/D 500 s-apr was applied to the study suture line</description>
          </group>
          <group group_id="O2">
            <title>Control - Manual Compression With Surgical Gauze</title>
            <description>Dry gauze pads were positioned to cover the complete study suture line</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Graft Occlusion</title>
          <description>Determined clinically and defined as absence of blood flow through the graft.</description>
          <population>Safety Analysis Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" lower_limit="2.6" upper_limit="14.7"/>
                    <measurement group_id="O2" value="11.4" lower_limit="5.4" upper_limit="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.380</p_value>
            <method>Likelihood ratio chi-square test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Infection at the Surgical Site</title>
        <time_frame>post-op discharge/day 1, post-op day 14 and day 30</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>FS VH S/D 500 S-apr</title>
            <description>FS VH S/D 500 s-apr was applied to the study suture line</description>
          </group>
          <group group_id="O2">
            <title>Control - Manual Compression With Surgical Gauze</title>
            <description>Dry gauze pads were positioned to cover the complete study suture line</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Infection at the Surgical Site</title>
          <population>Safety Analysis Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" lower_limit="4.4" upper_limit="18.4"/>
                    <measurement group_id="O2" value="7.1" lower_limit="2.6" upper_limit="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.545</p_value>
            <method>Likelihood ratio chi-square test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Infections by Grade</title>
        <description>Infections were recorded according to:
Grade I: only dermis affected
Grade II: infection invades subcutaneous region but not the arterial implant
Grade III: the arterial implant is infected</description>
        <time_frame>post-op discharge/day 1, post-op day 14 and day 30</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>FS VH S/D 500 S-apr</title>
            <description>FS VH S/D 500 s-apr was applied to the study suture line</description>
          </group>
          <group group_id="O2">
            <title>Control - Manual Compression With Surgical Gauze</title>
            <description>Dry gauze pads were positioned to cover the complete study suture line</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Infections by Grade</title>
          <description>Infections were recorded according to:
Grade I: only dermis affected
Grade II: infection invades subcutaneous region but not the arterial implant
Grade III: the arterial implant is infected</description>
          <population>Safety Analysis Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs: Systolic and Diastolic Blood Pressure (BP)- Preoperative Baseline</title>
        <time_frame>Within 14 days prior to date of surgery</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>FS VH S/D 500 S-apr</title>
            <description>FS VH S/D 500 s-apr was applied to the study suture line</description>
          </group>
          <group group_id="O2">
            <title>Control - Manual Compression With Surgical Gauze</title>
            <description>Dry gauze pads were positioned to cover the complete study suture line</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs: Systolic and Diastolic Blood Pressure (BP)- Preoperative Baseline</title>
          <population>Safety Analysis Set</population>
          <units>mm Hg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.5" lower_limit="86" upper_limit="197"/>
                    <measurement group_id="O2" value="143.5" lower_limit="90" upper_limit="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.0" lower_limit="47" upper_limit="104"/>
                    <measurement group_id="O2" value="76.5" lower_limit="50" upper_limit="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Vital Signs: Systolic and Diastolic Blood Pressure</title>
        <description>Percent Change in Systolic and Diastolic Blood Pressure (BP) Measured as: Preoperative Baseline - Intraoperative Day 0; Preoperative Baseline - Postoperative Day 1; and Preoperative Baseline - Postoperative Day 14</description>
        <time_frame>Within 14 days prior to surgery through postoperative day 14</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>FS VH S/D 500 S-apr: Preop Baseline - Intraoperative Day 0</title>
            <description>FS VH S/D 500 s-apr was applied to the study suture line</description>
          </group>
          <group group_id="O2">
            <title>Control: Preop Baseline - Intraoperative Day 0</title>
            <description>Manual compression with surgical gauze - Dry gauze pads were positioned to cover the complete study suture line</description>
          </group>
          <group group_id="O3">
            <title>FS VH S/D 500 S-apr: Preop Baseline - Postoperative Day 1</title>
            <description>FS VH S/D 500 s-apr was applied to the study suture line</description>
          </group>
          <group group_id="O4">
            <title>Control: Preop Baseline - Postoperative Day 1</title>
            <description>Manual compression with surgical gauze - Dry gauze pads were positioned to cover the complete study suture line</description>
          </group>
          <group group_id="O5">
            <title>FS VH S/D 500 S-apr: Preop Baseline - Postoperative Day 14</title>
            <description>FS VH S/D 500 s-apr was applied to the study suture line</description>
          </group>
          <group group_id="O6">
            <title>Control: Preop Baseline - Postoperative Day 14</title>
            <description>Manual compression with surgical gauze - Dry gauze pads were positioned to cover the complete study suture line</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Vital Signs: Systolic and Diastolic Blood Pressure</title>
          <description>Percent Change in Systolic and Diastolic Blood Pressure (BP) Measured as: Preoperative Baseline - Intraoperative Day 0; Preoperative Baseline - Postoperative Day 1; and Preoperative Baseline - Postoperative Day 14</description>
          <population>Safety Analysis Set</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="68"/>
                <count group_id="O6" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic BP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.63" lower_limit="-52.5" upper_limit="44.2"/>
                    <measurement group_id="O2" value="-12.46" lower_limit="-52.1" upper_limit="74.3"/>
                    <measurement group_id="O3" value="-8.33" lower_limit="-45.5" upper_limit="34.9"/>
                    <measurement group_id="O4" value="-7.72" lower_limit="-40.5" upper_limit="52.7"/>
                    <measurement group_id="O5" value="-2.59" lower_limit="-40.5" upper_limit="35.7"/>
                    <measurement group_id="O6" value="-2.94" lower_limit="-39.5" upper_limit="68.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic BP (Control Postoperative Day 14 N=64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.29" lower_limit="-52.9" upper_limit="50.0"/>
                    <measurement group_id="O2" value="-16.87" lower_limit="-49.5" upper_limit="33.9"/>
                    <measurement group_id="O3" value="-11.58" lower_limit="-49.4" upper_limit="55.3"/>
                    <measurement group_id="O4" value="-16.84" lower_limit="-56.6" upper_limit="32.8"/>
                    <measurement group_id="O5" value="-2.64" lower_limit="-40.2" upper_limit="58.2"/>
                    <measurement group_id="O6" value="-7.30" lower_limit="-50.5" upper_limit="41.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs: Heart Rate - Preoperative Baseline</title>
        <time_frame>Within 14 days prior to date of surgery</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>FS VH S/D 500 S-apr</title>
            <description>FS VH S/D 500 s-apr was applied to the study suture line</description>
          </group>
          <group group_id="O2">
            <title>Control - Manual Compression With Surgical Gauze</title>
            <description>Dry gauze pads were positioned to cover the complete study suture line</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs: Heart Rate - Preoperative Baseline</title>
          <population>Safety Analysis Set</population>
          <units>beats per minute</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" lower_limit="52" upper_limit="106"/>
                    <measurement group_id="O2" value="75.0" lower_limit="41" upper_limit="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Vital Signs: Heart Rate</title>
        <description>Percent Change in Heart Rate Measured as: Preoperative Baseline - Intraoperative Day 0; Preoperative Baseline - Postoperative Day 1; and Preoperative Baseline - Postoperative Day 14</description>
        <time_frame>Within 14 days prior to surgery through postoperative day 14</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>FS VH S/D 500 S-apr: Preop Baseline - Intraoperative Day 0</title>
            <description>FS VH S/D 500 s-apr was applied to the study suture line</description>
          </group>
          <group group_id="O2">
            <title>Control: Preop Baseline - Intraoperative Day 0</title>
            <description>Manual compression with surgical gauze - Dry gauze pads were positioned to cover the complete study suture line</description>
          </group>
          <group group_id="O3">
            <title>FS VH S/D 500 S-apr: Preop Baseline - Postoperative Day 1</title>
            <description>FS VH S/D 500 s-apr was applied to the study suture line</description>
          </group>
          <group group_id="O4">
            <title>Control: Preop Baseline - Postoperative Day 1</title>
            <description>Manual compression with surgical gauze - Dry gauze pads were positioned to cover the complete study suture line</description>
          </group>
          <group group_id="O5">
            <title>FS VH S/D 500 S-apr: Preop Baseline - Postoperative Day 14</title>
            <description>FS VH S/D 500 s-apr was applied to the study suture line</description>
          </group>
          <group group_id="O6">
            <title>Control: Preop Baseline - Postoperative Day 14</title>
            <description>Manual compression with surgical gauze - Dry gauze pads were positioned to cover the complete study suture line</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Vital Signs: Heart Rate</title>
          <description>Percent Change in Heart Rate Measured as: Preoperative Baseline - Intraoperative Day 0; Preoperative Baseline - Postoperative Day 1; and Preoperative Baseline - Postoperative Day 14</description>
          <population>Safety Analysis Set</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="68"/>
                <count group_id="O6" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.27" lower_limit="-34.2" upper_limit="32.4"/>
                    <measurement group_id="O2" value="-2.12" lower_limit="-37.5" upper_limit="123.8"/>
                    <measurement group_id="O3" value="5.44" lower_limit="-22.9" upper_limit="82.8"/>
                    <measurement group_id="O4" value="4.84" lower_limit="-36.5" upper_limit="84.0"/>
                    <measurement group_id="O5" value="5.63" lower_limit="-20.0" upper_limit="79.3"/>
                    <measurement group_id="O6" value="0.00" lower_limit="-23.8" upper_limit="81.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs: Respiratory Rate - Preoperative Baseline</title>
        <time_frame>Within 14 days prior to date of surgery</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>FS VH S/D 500 S-apr</title>
            <description>FS VH S/D 500 s-apr was applied to the study suture line</description>
          </group>
          <group group_id="O2">
            <title>Control - Manual Compression With Surgical Gauze</title>
            <description>Dry gauze pads were positioned to cover the complete study suture line</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs: Respiratory Rate - Preoperative Baseline</title>
          <population>Safety Analysis Set</population>
          <units>breaths per minute</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0" lower_limit="12" upper_limit="22"/>
                    <measurement group_id="O2" value="18.0" lower_limit="14" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Vital Signs: Respiratory Rate</title>
        <description>Percent Change in Heart Rate Measured as: Preoperative Baseline - Postoperative Day 1; and Preoperative Baseline - Postoperative Day 14</description>
        <time_frame>Within 14 days prior to surgery through postoperative day 14</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>FS VH S/D 500 S-apr: Preop Baseline - Postoperative Day 1</title>
            <description>FS VH S/D 500 s-apr was applied to the study suture line</description>
          </group>
          <group group_id="O2">
            <title>Control: Preop Baseline - Postoperative Day 1</title>
            <description>Manual compression with surgical gauze - Dry gauze pads were positioned to cover the complete study suture line</description>
          </group>
          <group group_id="O3">
            <title>FS VH S/D 500 S-apr: Preop Baseline - Postoperative Day 14</title>
            <description>FS VH S/D 500 s-apr was applied to the study suture line</description>
          </group>
          <group group_id="O4">
            <title>Control: Preop Baseline - Postoperative Day 14</title>
            <description>Manual compression with surgical gauze - Dry gauze pads were positioned to cover the complete study suture line</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Vital Signs: Respiratory Rate</title>
          <description>Percent Change in Heart Rate Measured as: Preoperative Baseline - Postoperative Day 1; and Preoperative Baseline - Postoperative Day 14</description>
          <population>Safety Analysis Set</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.00" lower_limit="-40.0" upper_limit="66.7"/>
                    <measurement group_id="O2" value="-9.55" lower_limit="-40.0" upper_limit="42.9"/>
                    <measurement group_id="O3" value="0.00" lower_limit="-40.0" upper_limit="55.6"/>
                    <measurement group_id="O4" value="-6.07" lower_limit="-40.0" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Values Over Time: Hemoglobin</title>
        <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
        <population>Safety Analysis Data Set</population>
        <group_list>
          <group group_id="O1">
            <title>FS VH S/D 500 S-apr: Baseline</title>
            <description>FS VH S/D 500 s-apr, 120 seconds polymerization</description>
          </group>
          <group group_id="O2">
            <title>FS VH S/D 500 S-apr: Postoperative Day 14</title>
            <description>FS VH S/D 500 s-apr, 120 seconds polymerization</description>
          </group>
          <group group_id="O3">
            <title>Control Group: Preoperative Baseline</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
          <group group_id="O4">
            <title>Control Group: Postoperative Day 14</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Values Over Time: Hemoglobin</title>
          <population>Safety Analysis Data Set</population>
          <units>g/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="67"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.10" lower_limit="9.0" upper_limit="15.4"/>
                    <measurement group_id="O2" value="11.60" lower_limit="8.1" upper_limit="14.5"/>
                    <measurement group_id="O3" value="12.20" lower_limit="9.0" upper_limit="18.4"/>
                    <measurement group_id="O4" value="11.80" lower_limit="8.2" upper_limit="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Values Over Time: Hematocrit</title>
        <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
        <population>Safety Analysis Data Set</population>
        <group_list>
          <group group_id="O1">
            <title>FS VH S/D 500 S-apr: Baseline</title>
            <description>FS VH S/D 500 s-apr, 120 seconds polymerization</description>
          </group>
          <group group_id="O2">
            <title>FS VH S/D 500 S-apr: Postoperative Day 14</title>
            <description>FS VH S/D 500 s-apr, 120 seconds polymerization</description>
          </group>
          <group group_id="O3">
            <title>Control Group: Preoperative Baseline</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
          <group group_id="O4">
            <title>Control Group: Postoperative Day 14</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Values Over Time: Hematocrit</title>
          <population>Safety Analysis Data Set</population>
          <units>percentage of red blood cells in blood</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.0" lower_limit="28" upper_limit="50"/>
                    <measurement group_id="O2" value="36.0" lower_limit="28" upper_limit="46"/>
                    <measurement group_id="O3" value="38.5" lower_limit="28" upper_limit="58"/>
                    <measurement group_id="O4" value="37.0" lower_limit="24" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Values Over Time: Erythrocytes</title>
        <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
        <population>Safety Analysis Data Set</population>
        <group_list>
          <group group_id="O1">
            <title>FS VH S/D 500 S-apr: Baseline</title>
            <description>FS VH S/D 500 s-apr, 120 seconds polymerization</description>
          </group>
          <group group_id="O2">
            <title>FS VH S/D 500 S-apr: Postoperative Day 14</title>
            <description>FS VH S/D 500 s-apr, 120 seconds polymerization</description>
          </group>
          <group group_id="O3">
            <title>Control Group: Preoperative Baseline</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
          <group group_id="O4">
            <title>Control Group: Postoperative Day 14</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Values Over Time: Erythrocytes</title>
          <population>Safety Analysis Data Set</population>
          <units>x10^6/µl</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="67"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.20" lower_limit="3.1" upper_limit="5.3"/>
                    <measurement group_id="O2" value="3.90" lower_limit="2.9" upper_limit="5.0"/>
                    <measurement group_id="O3" value="4.10" lower_limit="2.9" upper_limit="5.8"/>
                    <measurement group_id="O4" value="3.90" lower_limit="2.4" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Values Over Time: Leukocytes, Basophils, Eosinophils, Lymphocytes, Neutrophils, and Monocytes</title>
        <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
        <population>Safety Analysis Data Set</population>
        <group_list>
          <group group_id="O1">
            <title>FS VH S/D 500 S-apr: Baseline</title>
            <description>FS VH S/D 500 s-apr, 120 seconds polymerization</description>
          </group>
          <group group_id="O2">
            <title>FS VH S/D 500 S-apr: Postoperative Day 14</title>
            <description>FS VH S/D 500 s-apr, 120 seconds polymerization</description>
          </group>
          <group group_id="O3">
            <title>Control Group: Preoperative Baseline</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
          <group group_id="O4">
            <title>Control Group: Postoperative Day 14</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Values Over Time: Leukocytes, Basophils, Eosinophils, Lymphocytes, Neutrophils, and Monocytes</title>
          <population>Safety Analysis Data Set</population>
          <units>x10^3/µl</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="67"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Leukocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.105" lower_limit="2.46" upper_limit="14.83"/>
                    <measurement group_id="O2" value="8.260" lower_limit="3.85" upper_limit="14.16"/>
                    <measurement group_id="O3" value="6.760" lower_limit="2.93" upper_limit="15.00"/>
                    <measurement group_id="O4" value="7.980" lower_limit="3.51" upper_limit="13.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.040" lower_limit="0.00" upper_limit="0.11"/>
                    <measurement group_id="O2" value="0.040" lower_limit="0.00" upper_limit="0.11"/>
                    <measurement group_id="O3" value="0.040" lower_limit="0.00" upper_limit="0.20"/>
                    <measurement group_id="O4" value="0.050" lower_limit="0.00" upper_limit="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.180" lower_limit="0.00" upper_limit="0.96"/>
                    <measurement group_id="O2" value="0.200" lower_limit="0.00" upper_limit="0.81"/>
                    <measurement group_id="O3" value="0.160" lower_limit="0.05" upper_limit="0.61"/>
                    <measurement group_id="O4" value="0.220" lower_limit="0.00" upper_limit="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.805" lower_limit="0.16" upper_limit="4.55"/>
                    <measurement group_id="O2" value="1.800" lower_limit="0.29" upper_limit="3.74"/>
                    <measurement group_id="O3" value="1.700" lower_limit="0.54" upper_limit="4.61"/>
                    <measurement group_id="O4" value="1.750" lower_limit="0.69" upper_limit="4.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.585" lower_limit="0.67" upper_limit="11.30"/>
                    <measurement group_id="O2" value="5.570" lower_limit="2.50" upper_limit="11.04"/>
                    <measurement group_id="O3" value="4.560" lower_limit="1.32" upper_limit="12.19"/>
                    <measurement group_id="O4" value="5.150" lower_limit="2.02" upper_limit="10.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.370" lower_limit="0.09" upper_limit="1.02"/>
                    <measurement group_id="O2" value="0.430" lower_limit="0.12" upper_limit="1.17"/>
                    <measurement group_id="O3" value="0.400" lower_limit="0.15" upper_limit="0.98"/>
                    <measurement group_id="O4" value="0.460" lower_limit="0.13" upper_limit="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Values Over Time: Platelets</title>
        <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
        <population>Safety Analysis Data Set</population>
        <group_list>
          <group group_id="O1">
            <title>FS VH S/D 500 S-apr: Baseline</title>
            <description>FS VH S/D 500 s-apr, 120 seconds polymerization</description>
          </group>
          <group group_id="O2">
            <title>FS VH S/D 500 S-apr: Postoperative Day 14</title>
            <description>FS VH S/D 500 s-apr, 120 seconds polymerization</description>
          </group>
          <group group_id="O3">
            <title>Control Group: Preoperative Baseline</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
          <group group_id="O4">
            <title>Control Group: Postoperative Day 14</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Values Over Time: Platelets</title>
          <population>Safety Analysis Data Set</population>
          <units>x10^3/µl</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="67"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="227.0" lower_limit="77" upper_limit="562"/>
                    <measurement group_id="O2" value="303.0" lower_limit="92" upper_limit="643"/>
                    <measurement group_id="O3" value="239.0" lower_limit="66" upper_limit="646"/>
                    <measurement group_id="O4" value="283.0" lower_limit="116" upper_limit="661"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Values Over Time: Creatinine, Bilirubin, and Blood Urea Nitrogen (BUN)</title>
        <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
        <population>Safety Analysis Data Set</population>
        <group_list>
          <group group_id="O1">
            <title>FS VH S/D 500 S-apr: Baseline</title>
            <description>FS VH S/D 500 s-apr, 120 seconds polymerization</description>
          </group>
          <group group_id="O2">
            <title>FS VH S/D 500 S-apr: Postoperative Day 14</title>
            <description>FS VH S/D 500 s-apr, 120 seconds polymerization</description>
          </group>
          <group group_id="O3">
            <title>Control Group: Preoperative Baseline</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
          <group group_id="O4">
            <title>Control Group: Postoperative Day 14</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Values Over Time: Creatinine, Bilirubin, and Blood Urea Nitrogen (BUN)</title>
          <population>Safety Analysis Data Set</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Creatinine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.80" lower_limit="0.6" upper_limit="13.1"/>
                    <measurement group_id="O2" value="2.20" lower_limit="0.7" upper_limit="11.1"/>
                    <measurement group_id="O3" value="2.90" lower_limit="0.4" upper_limit="12.4"/>
                    <measurement group_id="O4" value="4.40" lower_limit="0.5" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" lower_limit="0.2" upper_limit="1.2"/>
                    <measurement group_id="O2" value="0.30" lower_limit="0.2" upper_limit="1.2"/>
                    <measurement group_id="O3" value="0.30" lower_limit="0.2" upper_limit="1.4"/>
                    <measurement group_id="O4" value="0.30" lower_limit="0.2" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.0" lower_limit="6" upper_limit="76"/>
                    <measurement group_id="O2" value="23.0" lower_limit="10" upper_limit="77"/>
                    <measurement group_id="O3" value="22.0" lower_limit="7" upper_limit="111"/>
                    <measurement group_id="O4" value="30.0" lower_limit="6" upper_limit="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Values Over Time: Alanine Aminotransferase (ALT)</title>
        <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
        <population>Safety Analysis Data Set</population>
        <group_list>
          <group group_id="O1">
            <title>FS VH S/D 500 S-apr: Baseline</title>
            <description>FS VH S/D 500 s-apr, 120 seconds polymerization</description>
          </group>
          <group group_id="O2">
            <title>FS VH S/D 500 S-apr: Postoperative Day 14</title>
            <description>FS VH S/D 500 s-apr, 120 seconds polymerization</description>
          </group>
          <group group_id="O3">
            <title>Control Group: Preoperative Baseline</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
          <group group_id="O4">
            <title>Control Group: Postoperative Day 14</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Values Over Time: Alanine Aminotransferase (ALT)</title>
          <population>Safety Analysis Data Set</population>
          <units>U/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" lower_limit="4" upper_limit="152"/>
                    <measurement group_id="O2" value="16.0" lower_limit="4" upper_limit="95"/>
                    <measurement group_id="O3" value="14.0" lower_limit="4" upper_limit="69"/>
                    <measurement group_id="O4" value="13.0" lower_limit="4" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Values Over Time: Aspartate Aminotransferase (AST)</title>
        <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
        <population>Safety Analysis Data Set</population>
        <group_list>
          <group group_id="O1">
            <title>FS VH S/D 500 S-apr: Baseline</title>
            <description>FS VH S/D 500 s-apr, 120 seconds polymerization</description>
          </group>
          <group group_id="O2">
            <title>FS VH S/D 500 S-apr: Postoperative Day 14</title>
            <description>FS VH S/D 500 s-apr, 120 seconds polymerization</description>
          </group>
          <group group_id="O3">
            <title>Control Group: Preoperative Baseline</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
          <group group_id="O4">
            <title>Control Group: Postoperative Day 14</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Values Over Time: Aspartate Aminotransferase (AST)</title>
          <population>Safety Analysis Data Set</population>
          <units>U/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.0" lower_limit="9" upper_limit="61"/>
                    <measurement group_id="O2" value="20.5" lower_limit="8" upper_limit="81"/>
                    <measurement group_id="O3" value="19.0" lower_limit="8" upper_limit="92"/>
                    <measurement group_id="O4" value="20.0" lower_limit="10" upper_limit="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Values Over Time: Activated Partial Thromboplastin Time (aPTT)</title>
        <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
        <population>Safety Analysis Data Set</population>
        <group_list>
          <group group_id="O1">
            <title>FS VH S/D 500 S-apr: Baseline</title>
            <description>FS VH S/D 500 s-apr, 120 seconds polymerization</description>
          </group>
          <group group_id="O2">
            <title>FS VH S/D 500 S-apr: Postoperative Day 14</title>
            <description>FS VH S/D 500 s-apr, 120 seconds polymerization</description>
          </group>
          <group group_id="O3">
            <title>Control Group: Preoperative Baseline</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
          <group group_id="O4">
            <title>Control Group: Postoperative Day 14</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Values Over Time: Activated Partial Thromboplastin Time (aPTT)</title>
          <population>Safety Analysis Data Set</population>
          <units>seconds</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.40" lower_limit="18.0" upper_limit="150.0"/>
                    <measurement group_id="O2" value="25.10" lower_limit="18.0" upper_limit="150.0"/>
                    <measurement group_id="O3" value="25.20" lower_limit="18.2" upper_limit="150.0"/>
                    <measurement group_id="O4" value="25.80" lower_limit="19.3" upper_limit="150.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Values Over Time: International Normalized Ratio(INR)</title>
        <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
        <population>Safety Analysis Data Set</population>
        <group_list>
          <group group_id="O1">
            <title>FS VH S/D 500 S-apr: Baseline</title>
            <description>FS VH S/D 500 s-apr, 120 seconds polymerization</description>
          </group>
          <group group_id="O2">
            <title>FS VH S/D 500 S-apr: Postoperative Day 14</title>
            <description>FS VH S/D 500 s-apr, 120 seconds polymerization</description>
          </group>
          <group group_id="O3">
            <title>Control Group: Preoperative Baseline</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
          <group group_id="O4">
            <title>Control Group: Postoperative Day 14</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Values Over Time: International Normalized Ratio(INR)</title>
          <population>Safety Analysis Data Set</population>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.9" upper_limit="3.6"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.9" upper_limit="4.1"/>
                    <measurement group_id="O3" value="1.00" lower_limit="0.9" upper_limit="1.5"/>
                    <measurement group_id="O4" value="1.00" lower_limit="0.9" upper_limit="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hemostasis at 4 Minutes After Treatment Application at the Suture Line by Bleeding Severity - Moderate Bleeding</title>
        <description>Investigators were shown videos of bleeding severities to standardize assessments.
Moderate bleeding defined as:
Either &gt;25% of the suture line bleeds, or
≥5 suture line bleedings were present, if counting of suture line bleedings was possible, or
1 pulsatile suture line bleeding was present.</description>
        <time_frame>4 minutes post start of treatment application</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>FS VH S/D 500 S-apr</title>
            <description>FS VH S/D 500 s-apr was applied to the study suture line</description>
          </group>
          <group group_id="O2">
            <title>Control - Manual Compression With Surgical Gauze</title>
            <description>Dry gauze pads were positioned to cover the complete study suture line</description>
          </group>
        </group_list>
        <measure>
          <title>Hemostasis at 4 Minutes After Treatment Application at the Suture Line by Bleeding Severity - Moderate Bleeding</title>
          <description>Investigators were shown videos of bleeding severities to standardize assessments.
Moderate bleeding defined as:
Either &gt;25% of the suture line bleeds, or
≥5 suture line bleedings were present, if counting of suture line bleedings was possible, or
1 pulsatile suture line bleeding was present.</description>
          <population>Intent to Treat</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.9" lower_limit="58.5" upper_limit="88.8"/>
                    <measurement group_id="O2" value="48.1" lower_limit="30.1" upper_limit="66.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hemostasis at 4 Minutes After Treatment Application at the Suture Line by Bleeding Severity - Severe Bleeding</title>
        <description>Investigators were shown videos of bleeding severities to standardize assessments.
Severe bleeding defined as:
Either &gt;50% of the suture line bleeds, or
≥10 suture line bleedings were present, if counting of suture line bleedings was possible, or
&gt;1 pulsatile suture line bleeding was present, or
≥1 spurting suture line bleeding was present.</description>
        <time_frame>4 minutes post start of treatment application</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>FS VH S/D 500 S-apr</title>
            <description>FS VH S/D 500 s-apr was applied to the study suture line</description>
          </group>
          <group group_id="O2">
            <title>Control - Manual Compression With Surgical Gauze</title>
            <description>Dry gauze pads were positioned to cover the complete study suture line</description>
          </group>
        </group_list>
        <measure>
          <title>Hemostasis at 4 Minutes After Treatment Application at the Suture Line by Bleeding Severity - Severe Bleeding</title>
          <description>Investigators were shown videos of bleeding severities to standardize assessments.
Severe bleeding defined as:
Either &gt;50% of the suture line bleeds, or
≥10 suture line bleedings were present, if counting of suture line bleedings was possible, or
&gt;1 pulsatile suture line bleeding was present, or
≥1 spurting suture line bleeding was present.</description>
          <population>Intent to Treat</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.7" lower_limit="38.5" upper_limit="68.4"/>
                    <measurement group_id="O2" value="20.9" lower_limit="10.7" upper_limit="34.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the study period, 1 year and 3 months. For SAEs: Recovering/resolving SAEs were followed until resolution, medically stabilized, or 30 days after study completion/termination visit, whichever came first.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>FS VH S/D 500 S-apr</title>
          <description>FS VH S/D 500 s-apr will be applied to the study suture line.</description>
        </group>
        <group group_id="E2">
          <title>Control - Manual Compression With Surgical Gauze Pads</title>
          <description>Dry gauze pads will be positioned to cover the complete study suture line.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Small intestinal perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Thrombosis in device</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Wound infection staphylococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Vascular graft occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Vascular graft thrombosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Drug toxicity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Graft thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Incision site cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ischaemic neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial thrombosis limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Steal syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="70"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Operative haemorrhage</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Baxter's agreements with PIs may vary per requirements of the individual PI, but contain common elements. For this study, PIs are restricted from independently publishing results until the earlier of the primary multicenter publication or 1 year after study completion. Baxter requires a review of results communications (e.g., for confidential information) ≥90 days prior to submission or communication. Baxter may request an additional delay of ≤60 days (e.g., for intellectual property protection)</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Edith Hantak, Dir, Global Therapeutic Area, BioSurgery</name_or_title>
      <organization>BAXTER INNOVATIONS GmbH</organization>
      <email>edith_hantak@baxter.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

